Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesFactors That Predict Risk of Thrombosis in Relatives of Patients With Unprovoked Venous Thromboembolism
Chest, 10/08/09
Couturaud F et al. – Unprovoked venous thromboembolism at a young age is associated with a substantially increased risk of venous thromboembolism in patients’ families.
Related Articles
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials
Circulation, 11/04/09
Relevance Score: 68%
Hematocrit and risk of venous thromboembolism in a general population. The Tromso Study
Haematologica, 10/21/09
Relevance Score: 68%
Risk factors and underlying mechanisms for venous stasis syndrome: a population-based case–control study
Vascular Medicine, 10/13/09
Relevance Score: 68%
Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER)
Annals of Oncology, 10/20/09
Relevance Score: 67%
2008 french national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group
Critical Reviews in Oncology/Hematology, 10/07/09
Relevance Score: 67%
Today in CV/Thromboembolic...keeping you current
Receive free subspecialty "5-minute updates" via email
The clinical course of pulmonary embolism patients anticoagulated for 1 year: results of a prospective, observational, cohort study
Journal of Thrombosis and Haemostasis, 12/18/09
Volumetric or time-based capnography for excluding pulmonary embolism in outpatients
Journal of Thrombosis and Haemostasis, 12/18/09
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
Rheumatology, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor